These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34913741)

  • 1. Treatment Options for T1 Stage Adenocarcinoma of Esophagogastric Junction: A Real-World Retrospective Cohort Study.
    Zhou X; Chen H; Li S; Hua J; Zhang W; Li X; Si X; Zhang G
    Cancer Control; 2021; 28():10732748211063955. PubMed ID: 34913741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Marital Status on the Survival of Patients With Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Study.
    Wang S; Chen L; Chen D; Chao J; Shao Y; Tang K; Chen W
    Cancer Control; 2021; 28():10732748211066309. PubMed ID: 34910613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stage III esophageal adenocarcinoma: definitive chemoradiation vs. chemoradiation plus surgery.
    Schlottmann F; Strassle PD; Gaber C; Patti MG
    Updates Surg; 2018 Dec; 70(4):423-426. PubMed ID: 29926306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
    Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
    JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable long-term outcomes after endoscopic therapy and gastrectomy of early adenocarcinoma of esophagogastric junction: a population-based study.
    GuoHui M; MingHua Z; ZhenYu C; JianHai L; ChunXi W; ZeLong Y
    Surg Endosc; 2022 Oct; 36(10):7521-7528. PubMed ID: 35352149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
    Zhu Z; Wang Y; Li F; Gao J; Han B; Wang R; Xue Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):149-155. PubMed ID: 30799537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of postoperative survival between early-onset and late-onset adenocarcinoma of esophagogastric junction: a population-based study.
    Chen L; Jin T; Fang Y; Wu G; Yuan Y
    J Gastroenterol Hepatol; 2024 Jun; 39(6):1073-1081. PubMed ID: 38353050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
    Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
    J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis.
    Zhou YJ; Lu XF; Meng JL; Wang XY; Zhang QW; Chen JN; Wang QW; Yan FR; Li XB
    BMC Cancer; 2021 Jul; 21(1):771. PubMed ID: 34217249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
    Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
    Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy.
    Stark AP; Ikoma N; Chiang YJ; Estrella JS; Das P; Minsky BD; Blum MM; Ajani JA; Mansfield P; Badgwell BD
    Ann Surg Oncol; 2019 Oct; 26(11):3602-3610. PubMed ID: 31350645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of auto-quantified tumor-infiltrating lymphocytes and the prognostic value in adenocarcinoma of the esophagogastric junction, gastric adenocarcinoma, and esophageal squamous cell carcinoma.
    Dong H; Yao L; Fan J; Gao P; Yang X; Yuan Z; Zhang T; Lu M; Chen X; Suo C
    Aging (Albany NY); 2024 Jul; 16(13):11027-11061. PubMed ID: 38975889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the value of 7th editions of UICC-AJCC esophageal and gastric cancer TNM staging systems for prognostic prediction of adenocarcinoma of esophagogastric junction (Siewert type II)].
    Shi GD; Luo ZL; Fu MY; Tian D; Zhang L; Zhang KP
    Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):916-21. PubMed ID: 25623766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma.
    Bekkar S; Gronnier C; Messager M; Robb WB; Piessen G; Mariette C;
    Ann Thorac Surg; 2014 Jan; 97(1):303-10. PubMed ID: 24200394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.
    Mitchell KG; Ikoma N; Nelson DB; Maru DM; Erasmus JJ; Weston BR; Vaporciyan AA; Antonoff MB; Mehran RJ; Rice DC; Roth JA; Swisher SG; Sepesi B; Walsh GL; Correa AM; Das P; Blum MA; Badgwell BD; Hofstetter WL
    Ann Thorac Surg; 2019 Sep; 108(3):845-851. PubMed ID: 31102632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of endoscopic resection and metachronous cancer after endoscopic resection for adenocarcinoma of the esophagogastric junction in Japan.
    Abe S; Ishihara R; Takahashi H; Ono H; Fujisaki J; Matsui A; Takahashi A; Goda K; Kawada K; Koike T; Takeuchi M; Tsuji Y; Hirasawa D; Oyama T
    Gastrointest Endosc; 2019 Jun; 89(6):1120-1128. PubMed ID: 30576649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities.
    Deng W; Yang Z; Dong X; Yu R; Wang W
    Cancer Med; 2021 Jan; 10(2):659-674. PubMed ID: 33314798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should adenosquamous esophageal cancer be treated like adenocarcinoma or squamous cell carcinoma?
    Gamboa AC; Meyer BI; Switchenko JM; Rupji M; Lee RM; Turgeon MK; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
    J Surg Oncol; 2020 Sep; 122(3):412-421. PubMed ID: 32462769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sites of distant metastases and the cancer-specific survival of metastatic Siewert type II esophagogastric junction adenocarcinoma: a population-based study.
    Chen K; Deng X; Yang Z; Yu D; Zhang X; Li W; Xie D; He Z; Cheng D
    Expert Rev Gastroenterol Hepatol; 2020 Jun; 14(6):491-497. PubMed ID: 32324423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.